High-Demand Oncology Targeted Therapy for Global Cancer Treatment Markets
Sunitinib Malate Capsules are a potent multi-targeted receptor tyrosine kinase inhibitor (TKI) used in modern oncology treatment protocols for advanced cancers. It is widely prescribed across regulated markets including the USA, EU (Germany & UK), Middle East (UAE), Latin America (Brazil), and Africa (South Africa) for its proven efficacy in inhibiting tumor angiogenesis and cancer cell proliferation.
Product Overview – Sunitinib Malate Capsules
Generic Name: Sunitinib Malate
Strengths Available: 12.5 mg / 25 mg / 50 mg capsules
Dosage Form: Hard gelatin capsules (oral administration)
Therapeutic Class: Tyrosine Kinase Inhibitor (TKI), Anti-cancer agent
Prescription Status: Prescription Only Medicine (Rx)
Global ATC Code: L01XE04
Key Oncology Indications (FDA / EMA Approved Uses)
Sunitinib Malate is indicated for treatment of:
Advanced Renal Cell Carcinoma (RCC) – metastatic kidney cancer
Gastrointestinal Stromal Tumor (GIST) – after imatinib resistance or intolerance
Pancreatic Neuroendocrine Tumors (pNET) – progressive, unresectable cases
Adjuvant treatment of RCC in high-risk post-nephrectomy patients
These indications make it a critical oncology drug in global cancer therapy protocols.
Mechanism of Action (MOA) – Anti-Angiogenic Targeted Therapy
Sunitinib Malate works by inhibiting multiple receptor tyrosine kinases such as:
VEGFR (Vascular Endothelial Growth Factor Receptors)
PDGFR (Platelet-Derived Growth Factor Receptors)
FLT3, KIT, and RET pathways
Clinical Impact:
Blocks tumor blood vessel formation (anti-angiogenesis)
Reduces tumor growth and metastasis
Controls cancer progression in advanced stages
Strengths & Dosage Flexibility for Oncology Treatment Protocols
12.5 mg Capsules – dose titration / adjustment therapy
25 mg Capsules – moderate dosing schedules
50 mg Capsules – standard therapeutic dose for RCC & GIST
Common Clinical Regimen
50 mg once daily for 4 weeks
Followed by 2 weeks off therapy (6-week cycle)
Global Market Demand & Export Opportunities
Sunitinib Malate Capsules are in high demand across regulated and semi-regulated pharmaceutical markets:
United States
Strong demand for generic oncology TKIs
Used in RCC and GIST treatment protocols
Germany & United Kingdom
High adoption in EU oncology treatment guidelines (EMA approved)
Growing demand for cost-effective generics
United Arab Emirates (UAE)
Rapid oncology market expansion
Import-driven pharmaceutical supply chain
Brazil (Latin America)
Public healthcare oncology procurement programs
Increasing demand for affordable targeted therapies
South Africa
High oncology burden and rising TKI usage
Government & hospital tender procurement
Why Choose Sunitinib Malate Capsules?
Clinically proven targeted cancer therapy
Multi-indication oncology drug (RCC, GIST, pNET)
Available in multiple strengths for dose optimization
Strong global regulatory acceptance (FDA / EMA aligned)
High demand in hospital supply & oncology distribution channels
Packaging & Supply Information
Secure blister / HDPE bottle packaging (export grade)
Complies with WHO-GMP manufacturing standards
Export documentation support available:
COA (Certificate of Analysis)
MSDS (Material Safety Data Sheet)
GMP Certificate
Regulatory dossiers for export markets
Target Buyers / Importers
Oncology hospitals & cancer treatment centers
Government health procurement agencies
International pharmaceutical distributors
Oncology drug wholesalers
Hospital tender suppliers
Global Export Inquiry
📦 Available for bulk export & international supply contracts
🌍 Serving: USA | Germany | UK | UAE | Brazil | South Africa
📩 Business Inquiry: info@cordiumpharma.com
📱 WhatsApp: +91-9405117673
Compliance Disclaimer
This product is intended for regulated pharmaceutical distribution channels only. Usage must comply with local regulatory authority guidelines in each importing country.
Sunitinib Malate Capsules are a potent multi-targeted receptor tyrosine kinase inhibitor (TKI) used in modern oncology treatment protocols for advanced cancers. It is widely prescribed across regulated markets including the USA, EU (Germany & UK), Middle East (UAE), Latin America (Brazil), and Africa (South Africa) for its proven efficacy in inhibiting tumor angiogenesis and cancer cell proliferation.
Product Overview – Sunitinib Malate Capsules
Generic Name: Sunitinib Malate
Strengths Available: 12.5 mg / 25 mg / 50 mg capsules
Dosage Form: Hard gelatin capsules (oral administration)
Therapeutic Class: Tyrosine Kinase Inhibitor (TKI), Anti-cancer agent
Prescription Status: Prescription Only Medicine (Rx)
Global ATC Code: L01XE04
Key Oncology Indications (FDA / EMA Approved Uses)
Sunitinib Malate is indicated for treatment of:
Advanced Renal Cell Carcinoma (RCC) – metastatic kidney cancer
Gastrointestinal Stromal Tumor (GIST) – after imatinib resistance or intolerance
Pancreatic Neuroendocrine Tumors (pNET) – progressive, unresectable cases
Adjuvant treatment of RCC in high-risk post-nephrectomy patients
These indications make it a critical oncology drug in global cancer therapy protocols.
Mechanism of Action (MOA) – Anti-Angiogenic Targeted Therapy
Sunitinib Malate works by inhibiting multiple receptor tyrosine kinases such as:
VEGFR (Vascular Endothelial Growth Factor Receptors)
PDGFR (Platelet-Derived Growth Factor Receptors)
FLT3, KIT, and RET pathways
Clinical Impact:
Blocks tumor blood vessel formation (anti-angiogenesis)
Reduces tumor growth and metastasis
Controls cancer progression in advanced stages
Strengths & Dosage Flexibility for Oncology Treatment Protocols
12.5 mg Capsules – dose titration / adjustment therapy
25 mg Capsules – moderate dosing schedules
50 mg Capsules – standard therapeutic dose for RCC & GIST
Common Clinical Regimen
50 mg once daily for 4 weeks
Followed by 2 weeks off therapy (6-week cycle)
Global Market Demand & Export Opportunities
Sunitinib Malate Capsules are in high demand across regulated and semi-regulated pharmaceutical markets:
United States
Strong demand for generic oncology TKIs
Used in RCC and GIST treatment protocols
Germany & United Kingdom
High adoption in EU oncology treatment guidelines (EMA approved)
Growing demand for cost-effective generics
United Arab Emirates (UAE)
Rapid oncology market expansion
Import-driven pharmaceutical supply chain
Brazil (Latin America)
Public healthcare oncology procurement programs
Increasing demand for affordable targeted therapies
South Africa
High oncology burden and rising TKI usage
Government & hospital tender procurement
Why Choose Sunitinib Malate Capsules?
Clinically proven targeted cancer therapy
Multi-indication oncology drug (RCC, GIST, pNET)
Available in multiple strengths for dose optimization
Strong global regulatory acceptance (FDA / EMA aligned)
High demand in hospital supply & oncology distribution channels
Packaging & Supply Information
Secure blister / HDPE bottle packaging (export grade)
Complies with WHO-GMP manufacturing standards
Export documentation support available:
COA (Certificate of Analysis)
MSDS (Material Safety Data Sheet)
GMP Certificate
Regulatory dossiers for export markets
Target Buyers / Importers
Oncology hospitals & cancer treatment centers
Government health procurement agencies
International pharmaceutical distributors
Oncology drug wholesalers
Hospital tender suppliers
Global Export Inquiry
📦 Available for bulk export & international supply contracts
🌍 Serving: USA | Germany | UK | UAE | Brazil | South Africa
📩 Business Inquiry: info@cordiumpharma.com
📱 WhatsApp: +91-9405117673
Compliance Disclaimer
This product is intended for regulated pharmaceutical distribution channels only. Usage must comply with local regulatory authority guidelines in each importing country.
Keywords
